Skip to search formSkip to main contentSkip to account menu

Zosuquidar

Known as: (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol 
A difluorocyclopropyl quinoline. Zosuquidar binds with high affinity to P-glycoprotein and inhibits P-glycoprotein-mediated multidrug resistance (MDR… 
National Institutes of Health

Related topics

Related topics

1 relation
zosuquidar trihydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Newly Synthesized Oxygenated Xanthones as Potential P-Glycoprotein Activators: In Vitro, Ex Vivo, and In Silico Studies
P-glycoprotein (P-gp) plays a crucial role in the protection of susceptible organs, by significantly decreasing the absorption… 
2019
2019
Intracellular Doppler Spectroscopy detects altered drug response in SKOV3 tumor spheroids with silenced or inhibited P-glycoprotein.
2017
2017
Data demonstrating the challenges of determining the kinetic parameters of P-gp mediated transport of low-water soluble substrates
2014
2014
P‐glycoprotein inhibition promotes prednisone retention in human sinonasal polyp explants
P‐glycoprotein (P‐gp) is an efflux pump, which is part of the innate chemo‐immunity defense system and is overexpressed in… 
2013
2013
Site dependent intestinal absorption of darunavir and its interaction with ketoconazole.
Review
2012
Review
2012
Leukaemic stem cells: drug resistance, metastasis and therapeutic implications.
Although there have been many new developments in the treatment of leukaemia with the use of new anti-leukaemic agents and stem… 
2008
2008
ABC transporters and the accumulation of imatinib and its active metabolite CGP74588 in rat C6 glioma cells.
2006
2006
DEPENDENCE OF NELFINAVIR BRAIN UPTAKE ON DOSE AND TISSUE CONCENTRATIONS OF THE SELECTIVE P-GLYCOPROTEIN INHIBITOR ZOSUQUIDAR IN RATS
Most reverse transcriptase and protease inhibitors used in highly active antiretroviral therapy for treating human… 
2006
2006
A Randomized, Placebo-Controlled, Double Blind Trial of the MDR Modulator, Zosuquidar, during Conventional Induction and Post-Remission Therapy for Pts > 60 Years of Age with Newly Diagnosed Acute…
A major limitation of therapeutic modulation of MDR1/Pglycoprotein mediated drug efflux is the pharmacokinetic interaction that… 
2005
2005
Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours
AbstractBackgroundZosuquidar (LY335979) is an oral P-glycoprotein modulator. This phase I study was designed to determine the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)